In this video, Motley Fool health-care analyst David Williamson discusses what investors can expect from Celgene's (NASDAQ: CELG ) upcoming earnings report and what to look for going forward.
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.